Clinical Trial Update: Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Pegylated Interferon-alpha-2a in patients with malignant melanoma (Stage IIA-IIIB) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Melanoma | Phase 3 | Status: COMPLETED